Concepedia

Delan Khalid

DK

Statistics

Publications

5

Citations

221

H-Index

5

Active since

2018

Affiliations

Dana-Farber Cancer Institute(Current)

Boston Children's Hospital

Broad Institute

Harvard University

Stanford University

Delan Khalid is an author at Dana-Farber Cancer Institute specializing in neuroblastoma biology, molecular oncology, and life sciences.

Publications per year

2018–2024

5

Publications

5

Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1

Nathaniel W. Mabe, Min Huang, Guillermo Nicolás Dalton et al. · Nature Cancer · 2022 · 110 citations · Full text

Medicine, Neuroscience, Oncology +12

Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression

Clarissa D. Staton, Jazmine D. W. Yaeger, Delan Khalid et al. · Neuropharmacology · 2018 · 71 citations · Full text

Life Sciences, Behavioral Sciences, Neuroscience +17

Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors

Clare F. Malone, Minjee Kim, Gabriela Alexe et al. · Cancer Research · 2022 · 17 citations · Full text

Medicine, Cancer Biology, Oncology +17

Inherent genome instability underlies trisomy 21-associated myeloid malignancies

Chun-Chin Chen, Rebecca E. Silberman, Duanduan Ma et al. · Leukemia · 2024 · 13 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14

Combining Menin and MEK Inhibition to Target Poor Prognostic <i>KMT2A</i>-Rearranged RAS Pathway-Mutant Acute Leukemia

Nastassja K. Scheidegger, Gabriela Alexe, Delan Khalid et al. · Blood · 2023 · 10 citations

Medicine, Molecular Biology, Oncology +17

1–5 of 5